All In Biotech

Drug Trial Radar · NCT07224269

Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis

A Pilot Study of the Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Aug 12, 2026

Primary completion

Aug 1, 2027

Study completion Oct 31, 2027

Sponsor

Lead sponsor
University of IowaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a single center, randomized, double-blind, placebo-controlled pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (mg) per os (PO) daily for patients with amyotrophic lateral sclerosis (ALS). The primary outcome of this study is to determine whether TZ increases adenosine triphosphate (ATP) levels in ALS. The investigators will measure adverse outcomes, safety, and tolerability of taking TZ. Procedures include blood draws, spirometry, fluorodeoxyglucose-positron emission tomography (FDG-PET) scans, questionnaires, and physical examinations. TZ will be titrated up to 5 mg PO daily. This is a pilot study and is not powered to assess efficacy of this medication. The investigators' hope is that this study will guide future studies of this (and similar) medications for the disease modification of ALS. This study also aims to learn more about how patients produce and use energy and if TZ can help to reverse energy deficits that appear in ALS.

Conditions

  • Amyotrophic Lateral Sclerosis
  • Adenosine Triphosphate Activities

Interventions

  • TerazosineDrug

    Titrating up to 5 mg PO at bedtime. Trial participants will take terazosin for 12 weeks.

  • PlaceboDrug

    Placebo matching terazosin tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in ATP levelsTime frame: Baseline and 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.